What does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL…
What is Phio Pharmaceuticals Corp.'s P/E and P/B ratio?
Phio Pharmaceuticals Corp. has a P/E ratio of -0.7 and a P/B ratio of 0.80.
What is Phio Pharmaceuticals Corp.'s debt-to-equity ratio?
Phio Pharmaceuticals Corp. has a debt-to-equity ratio of 0.00.
How much does Phio Pharmaceuticals Corp. owe compared with what it owns?
Phio Pharmaceuticals Corp. owes $0.12 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Phio Pharmaceuticals Corp.'s Positivity rank?
Phio Pharmaceuticals Corp. is ranked #1,424 of 6,775 companies globally and #296 of 4,000 in United States on PositoAI, with a Positivity Score of 22,877.
Does Phio Pharmaceuticals Corp. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Phio Pharmaceuticals Corp..
Where can I read the latest news about Phio Pharmaceuticals Corp.?
Recent headlines about Phio Pharmaceuticals Corp. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Phio Pharmaceuticals Corp. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Phio Pharmaceuticals Corp.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.